Nomura Holdings Inc. Makes New $352,000 Investment in Hologic, Inc. (NASDAQ:HOLX)

Nomura Holdings Inc. bought a new position in Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 4,930 shares of the medical equipment provider’s stock, valued at approximately $352,000.

Several other institutional investors have also made changes to their positions in the company. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Hologic in the 4th quarter valued at approximately $27,000. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Hologic by 69.4% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 554 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 227 shares in the last quarter. Allworth Financial LP boosted its position in shares of Hologic by 39.3% in the fourth quarter. Allworth Financial LP now owns 634 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 179 shares during the period. Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Hologic by 145.3% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 468 shares in the last quarter. Finally, BKM Wealth Management LLC acquired a new position in Hologic during the fourth quarter valued at $86,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $73.07 on Friday. The stock has a market capitalization of $17.05 billion, a P/E ratio of 37.28, a P/E/G ratio of 2.40 and a beta of 1.00. The business has a 50-day moving average of $74.59 and a two-hundred day moving average of $74.17. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $82.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. During the same quarter in the prior year, the business earned $1.06 earnings per share. The company’s revenue was down .8% on a year-over-year basis. On average, equities research analysts predict that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Friday, May 3rd. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Evercore ISI boosted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, JPMorgan Chase & Co. increased their price objective on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $85.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.